News | February 09, 2026
Wanbury reports explosive Q3 profit surge, signals strong growth ahead
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
